Aurora Cannabis Q1 FY27: Net Loss Narrows, Material Weakness Persists, $46M Cash Unlock Ahead
ACB is trading near its 52-week low of $2.56 (11% above the low).
Summary
Aurora Cannabis reported a narrower Q1 FY27 net loss of C$4.0M but lower adjusted EBITDA of C$3.4M. The material weakness in internal controls remains, while a planned release of ~C$46.4M in restricted cash could significantly strengthen the balance sheet.
Key Events · Earnings and Guidance · ACB
-
Q1 FY27 Net Loss Narrows
Net loss from continuing operations was C$4.0M, improved from C$10.2M a year ago, but adjusted EBITDA fell to C$3.4M from C$10.8M due to lower gross margins.
-
Material Weakness Unremediated
The material weakness in ICFR related to biological assets and inventory valuation, first disclosed in the FY26 annual report, remains unremediated as of June 30, 2026.
-
$46.4M Restricted Cash to Be Released
Subsequent to quarter-end, the Board approved winding up the segregated cell insurance program, which will release ~C$46.4M of restricted cash to unrestricted cash by Q3 FY27.
-
ATM Program Used, $87.1M Remaining
During Q1, Aurora raised C$6.8M in gross proceeds under its US$100M ATM program, with US$87.1M still available for future sales, representing potential dilution.
Analysis · ACB · Life Sciences
Aurora's Q1 FY27 results show a narrower net loss of C$4.0M vs. C$10.2M a year ago, but adjusted EBITDA fell to C$3.4M from C$10.8M as gross margins compressed. The material weakness in internal controls over biological assets and inventory valuation remains unremediated — a red flag that has persisted since the FY26 annual filing. On the positive side, the company expects to release ~C$46.4M in restricted cash by Q3 FY27, which would nearly double its unrestricted cash position and ease liquidity concerns. The ATM program was used to raise C$6.8M during the quarter, with US$87.1M still available, signaling potential future dilution.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 35% of the 1115 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $174.1M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.